Page 35 - GPD-3-2

Gene & Protein in Disease Review of CAR-T in ADs

Rheumatol. 2021;73(11):1954-1965. intranasal delivery. J Neuroinflammation. 2012;9:112.
doi: 10.1002/art.41812 doi: 10.1186/1742-2094-9-112
71. Nepom GT, Byers P, Seyfried C, et al. HLA genes associated 82. De Paula Pohl A, Schmidt A, Zhang AH, Maldonado T,
with rheumatoid arthritis. Identification of susceptibility Königs C, Scott DW. Engineered regulatory T cells expressing
alleles using specific oligonucleotide probes. Arthritis myelin-specific chimeric antigen receptors suppress EAE
Rheum. 1989;32(1):15-21. progression. Cell Immunol. 2020;358:104222.
doi: 10.1002/anr.1780320104 doi: 10.1016/j.cellimm.2020.104222
72. Whittington KB, Prislovsky A, Beaty J, Albritton L, Radic 83. Huang J, Huang X, Huang J. CAR-T cell therapy for
M, Rosloniec EF. CD8(+) T cells expressing an HLA-DR1 hematological malignancies: Limitations and optimization
chimeric antigen receptor target autoimmune CD4(+) T cells strategies. Front Immunol. 2022;13:1019115.
in an antigen-specific manner and inhibit the development doi: 10.3389/fimmu.2022.1019115
of autoimmune arthritis. J Immunol. 2022;208(1):16-26.
84. Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived
doi: 10.4049/jimmunol.2100643
IL-1 and IL-6 are differentially required for cytokine-release
73. Loftus EV Jr. Clinical epidemiology of inflammatory syndrome and neurotoxicity due to CAR T cells. Nat Med.
bowel disease: Incidence, prevalence, and environmental 2018;24(6):739-748.
influences. Gastroenterology. 2004;126(6):1504-1517.
doi: 10.1038/s41591-018-0036-4
doi: 10.1053/j.gastro.2004.01.063
85. Wehrli M, Gallagher K, Chen YB, et al. Single-center
74. Ochs HD, Gambineri E, Torgerson TR. IPEX, FOXP3 and experience using anakinra for steroid-refractory immune
regulatory T-cells: A model for autoimmunity. Immunol Res. effector cell-associated neurotoxicity syndrome (ICANS).
2007;38(1-3):112-121. J Immunother Cancer. 2022;10(1):e003847.
doi: 10.1007/s12026-007-0022-2 doi: 10.1136/jitc-2021-003847
75. Ye C, Yano H, Workman CJ, Vignali DAA. Interleukin-35: 86. Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M,
Structure, function and its impact on immune-related Piersigilli A, Sadelain M. CAR T cell-induced cytokine
diseases. J Interferon Cytokine Res. 2021;41(11):391-406. release syndrome is mediated by macrophages and abated
by IL-1 blockade. Nat Med. 2018;24(6):731-738.
doi: 10.1089/jir.2021.0147
doi: 10.1038/s41591-018-0041-7
76. Rubtsov YP, Rasmussen JP, Chi EY, et al. Regulatory T cell-
derived interleukin-10 limits inflammation at environmental 87. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor
interfaces. Immunity. 2008;28(4):546-558. T cells for sustained remissions in leukemia. N Engl J Med.
2014;371(16):1507-1517.
doi: 10.1016/j.immuni.2008.02.017
doi: 10.1056/NEJMoa1407222
77. Elinav E, Waks T, Eshhar Z. Redirection of regulatory
T cells with predetermined specificity for the treatment 88. Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS.
of experimental colitis in mice. Gastroenterology. Silencing the cytokine storm: The use of intravenous
2008;134(7):2014-2024. anakinra in haemophagocytic lymphohistiocytosis or
macrophage activation syndrome. Lancet Rheumatol.
doi: 10.1053/j.gastro.2008.02.060
2020;2(6):e358-e367.
78. Blat D, Zigmond E, Alteber Z, Waks T, Eshhar Z. doi: 10.1016/s2665-9913(20)30096-5
Suppression of murine colitis and its associated cancer by
carcinoembryonic antigen-specific regulatory T cells. Mol 89. Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition
Ther. 2014;22(5):1018-1028. reduces cytokine release syndrome and neuroinflammation
but enhances CAR-T cell function in xenografts. Blood.
doi: 10.1038/mt.2014.41
2019;133(7):697-709.
79. McFarland HF, Martin R. Multiple sclerosis: A complicated doi: 10.1182/blood-2018-10-881722
picture of autoimmunity. Nat Immunol. 2007;8(9):913-919.
90. Razeghian E, Nasution MKM, Rahman HS, et al. A deep
doi: 10.1038/ni1507
insight into CRISPR/Cas9 application in CAR-T cell-based
80. Dendrou CA, Fugger L, Friese MA. Immunopathology of tumor immunotherapies. Stem Cell Res Ther. 2021;12(1):428.
multiple sclerosis. Nat Rev Immunol. 2015;15(9):545-558.
doi: 10.1186/s13287-021-02510-7
doi: 10.1038/nri3871
91. Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis
81. Fransson M, Piras E, Burman J, et al. CAR/FoxP3-engineered as a safety switch for adoptive cell therapy. N Engl J Med.
T regulatory cells target the CNS and suppress EAE upon 2011;365(18):1673-1683.

Volume 3 Issue 2 (2024) 14 doi: 10.36922/gpd.2851